

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A process for human vitreous liquefaction comprising the steps of:

delivering a dose of plasmin in a range of less than 0.4 units to about .01 units and in a volume of about 0.1 cubic centimeters into a vitreous body of a subject human eye; and

incubating the plasmin in the vitreous body for a predetermined amount of time to create a liquefied vitreous.

2. (Original) The process of claim 1 wherein the delivering is by injection.

3. (Original) The process of claim 1 wherein the delivering is by infusion.

4. (Original) The process of claim 1 wherein the delivering is by sustained release intraocular device.

5. (Previously Presented) The process of claim 1 wherein the plasmin comprises human plasmin.

6. (Previously Presented) The process of claim 1 wherein the plasmin comprises autologous human plasmin.

7. (Previously Presented) The process of claim 1 wherein the plasmin comprises an accompaniment selected from the group consisting of: an enzyme, a glycoprotein, a

polysaccharide, an antibiotic, a pharmaceutically acceptable diluent, a pharmaceutically acceptable adjuvant and a pharmaceutically acceptable carrier.

8. (Original) The process of claim 1 further comprising the step of delivering a plasmin inhibitor.

9. (Original) The process of claim 1 wherein the subject eye has a pathological condition.

10. (Original) The process of claim 9 wherein the pathological condition is selected from the group consisting of: diabetic retinopathy, macular hole, macular pucker, intraocular infection, foreign intraocular material and retinal detachment.

Claims 11 and 12 (Canceled)

13. (Previously Amended) The process of claim 1 wherein the predetermined amount of time is between ten minutes and two hours.

14. (Currently Amended) A process for human vitreous liquefaction comprising the steps of:

delivering a dose of plasmin in a range of less than 0.4 units to about .01 units and in a volume of about 0.1 cubic centimeters comprising autologous plasmin into a vitreous body of a subject human eye; and

incubating the plasmin in the vitreous body for a predetermined amount of time to induce vitreous liquefaction.

15. (Original) The process of claim 14 wherein the delivering is by injection.
16. (Original) The process of claim 14 wherein the delivering is by infusion.
17. (Original) The process of claim 14 wherein the delivering is by sustained release intraocular device.
18. (Previously Presented) The process of claim 14 wherein the plasmin comprises an accompaniment selected from the group consisting of: an enzyme, a glycoprotein, a polysaccharide, an antibiotic, a pharmaceutically acceptable diluent, a pharmaceutically acceptable adjuvant and a pharmaceutically acceptable carrier.
19. (Original) The process of claim 14 further comprising the step of delivering a plasmin inhibitor.
20. (Original) The process of claim 14 wherein the subject eye has a pathological condition.

21. (Original) The process of claim 20 wherein the pathological condition is selected from the group consisting of: diabetic retinopathy, macular hole, macular pucker, intraocular infection, foreign intraocular material and retinal detachment.

Claims 22 and 23 (Canceled)

24. (Previously Presented) The process of claim 14 wherein the predetermined amount of time is between ten minutes and two hours.

25. (Previously Presented) The process of claim 1 further comprising the step of suctioning the liquefied vitreous from the subject human eye.

26. (Previously Presented) The process of claim 25 wherein suctioning is performed through a 25 or finer gauge instrument.

27. (Previously Presented) The process of claim 14 further comprising the step of suctioning the liquefied vitreous from the subject human eye.

28. (Previously Presented) The process of claim 27 wherein suctioning is performed through a 25 or finer gauge instrument.